Roivant Sciences (ROIV) Q4 2025 Earnings
Roivant Sciences reported Q4 2025 revenue of $2.0M (-77.8% YoY), missed analyst consensus of $5.1M by $3.1M. Diluted EPS came in at $-0.24 (-84.6% YoY), beat the $-0.30 consensus by $0.06. Roivant Sciences reports across 2 business segments, led by Biopharmaceutical Pipeline and Technology & Discovery Platforms.
Financial Snapshot
Trailing eight quarters through Q4 2025
Q4 2025 Earnings FAQ
Common questions about Roivant Sciences's Q4 2025 earnings report.
Roivant Sciences (ROIV) reported Q4 2025 earnings on February 6, 2026 before market open.
Roivant Sciences reported revenue of $2.0M and diluted EPS of $-0.24 for Q4 2025.
Revenue missed the consensus estimate of $5.1M by $3.1M. EPS beat the consensus estimate of $-0.30 by $0.06.
Compared to the same quarter a year prior, revenue declined 77.8% from $9.0M a year earlier and diluted EPS declined 84.6% from $-0.13.
You can read the 8-K earnings release (0001635088-26-000009) and the 10-Q periodic report (0001635088-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.